May 12 webcast to cover IMUNON's Q1 results, Phase 3 ovarian cancer update
IMUNON (NASDAQ: IMNN) will host a conference call on May 12, 2026, to discuss its first-quarter 2026 financial results and provide an update on the Phase 3 clinical development of its lead candidate, IMNN-001, for advanced ovarian cancer. The company has previously utilized such calls to highlight progress on IMNN-001, with past announcements generating mixed stock price reactions. This event is expected to clarify trial progress, financing, and any changes from previous updates.
MAR 31·GlobeNewswire▲
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMUNON, Inc. (Nasdaq: IMNN) reported its financial results for the year ended December 31, 2025, detailing a net loss of $14.5 million. The company highlighted significant progress in its pivotal Phase 3 OVATION 3 Study for IMNN-001 in advanced ovarian cancer, with final Phase 2 data showing continued improvements in median overall survival. IMUNON also discussed its PlaCCine DNA vaccine technology and strategic efforts to reduce operating expenses while advancing its lead candidate.
MAR 24·TipRanks→
Imunon Expands At-The-Market Equity Offering Capacity
Imunon (IMNN) has expanded its at-the-market (ATM) equity offering capacity to $17 million by registering an additional $7 million of common stock with H.C. Wainwright & Co. This move indicates the company's ongoing reliance on public equity markets for funding, which could lead to future shareholder dilution. While an analyst has a Buy rating on IMNN with a $25.00 price target, TipRanks' AI Analyst, Spark, rates it Neutral due to weak financial performance and technical downtrends, despite positive earnings call updates.
